X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80) 80
index medicus (68) 68
adult (52) 52
male (51) 51
female (50) 50
hiv infections - drug therapy (41) 41
infectious diseases (39) 39
middle aged (39) 39
hiv (34) 34
human immunodeficiency virus--hiv (30) 30
hiv infections - virology (27) 27
antiretroviral therapy (26) 26
virology (24) 24
immunology (22) 22
research (22) 22
hiv infection (21) 21
antiviral agents (20) 20
drug therapy (20) 20
hiv infections - immunology (20) 20
viral load (20) 20
hiv-1 - genetics (19) 19
microbiology (19) 19
pharmacology & pharmacy (18) 18
hiv-1 - drug effects (16) 16
mutation (16) 16
treatment outcome (16) 16
acquired immune deficiency syndrome--aids (15) 15
anti-hiv agents - therapeutic use (15) 15
health aspects (15) 15
medicine (15) 15
aids (14) 14
antiretroviral drugs (14) 14
drug resistance (14) 14
drug resistance, viral (14) 14
abridged index medicus (13) 13
analysis (13) 13
care and treatment (13) 13
hiv-1 (13) 13
infection (13) 13
multidisciplinary sciences (13) 13
protease inhibitors (13) 13
rna, viral - blood (13) 13
drug therapy, combination (12) 12
human immunodeficiency virus (12) 12
human-immunodeficiency-virus (12) 12
research article (12) 12
science (12) 12
t cells (12) 12
therapy (12) 12
anti-hiv agents - administration & dosage (11) 11
cd4 lymphocyte count (11) 11
clinical trials (11) 11
hiv-1-infected patients (11) 11
immunodeficiency-virus type-1 (11) 11
viruses (11) 11
active antiretroviral therapy (10) 10
aged (10) 10
antiretroviral agents (10) 10
dosage and administration (10) 10
hiv-1 - immunology (10) 10
hiv-1 - isolation & purification (10) 10
infections (10) 10
medicine, general & internal (10) 10
patients (10) 10
replication (10) 10
risk factors (10) 10
adolescent (9) 9
cd4 antigen (9) 9
hiv-1 - physiology (9) 9
prevalence (9) 9
anti-hiv agents - pharmacology (8) 8
double-blind (8) 8
double-blind method (8) 8
genotype (8) 8
hiv patients (8) 8
infectious disease (8) 8
rna (8) 8
studies (8) 8
virus diseases (8) 8
acquired immune deficiency syndrome (7) 7
adults (7) 7
anti-hiv agents - adverse effects (7) 7
cd4-positive t-lymphocytes - virology (7) 7
cohort studies (7) 7
expression (7) 7
hiv infections - blood (7) 7
hiv infections - complications (7) 7
hiv protease inhibitors - therapeutic use (7) 7
internal medicine (7) 7
medicine and health sciences (7) 7
molecular sequence data (7) 7
raltegravir (7) 7
ritonavir (7) 7
sida -- tractament (7) 7
usage (7) 7
vih (7) 7
antiretroviral therapy, highly active (6) 6
antiretroviral therapy, highly active - methods (6) 6
cd4 t-cells (6) 6
cells, cultured (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 5, pp. 363 - 371
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Summary Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 587 - 596
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2222 - 2231
Journal Article